ClinicalTrials.gg
TerminatedNCT01071902Updated Dec 3, 2012

Safety and Efficacy of Moxidex Otic

A Phase 3 interventional study of Moxidex otic solution and Moxifloxacin otic solution in Acute Otitis Media, sponsored by Alcon Research. Terminated at 1 site in United States. Open to participants aged 6 Months to 12 Years. Per ClinicalTrials.gov, last updated 2012-12-03.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Why this study was terminated
Management decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
6 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Otitis Media by Alcon — none open to participants now, none under way, none of them phase 3. Otitis Media · Alcon.

Started
2010
the only one that year
Phase 3
5 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Otitis Media by Alcon, this one is the only one that started in 2010, is one of 5 in phase 3, and was the 5th registered.

Otitis Media

241 studies on the registry are indexed under Otitis Media; 32 are open to participants now.

Browse Otitis Media studies →

Open to participants now

None of the 10 studies in Otitis Media by Alcon is open now. The open studies under Otitis Media, anywhere →

Where they have run

Who these studies take

Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 6 Months to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Otitis Media by Alcon as a file.
02

Study summary

The purpose of this study is to determine if Moxidex otic solution is safe and effective in treating middle ear infections in patients with ear tubes.

03

Conditions studied

  • Acute Otitis Media

Browse trials for

Keywords

  • ear tubes
  • ear drainage
  • ear infection
  • ear drops
  • acute otitis media
04

Who can participate

Ages eligible
6 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 6 months to 12 years of age
  • Ear tubes in one or both ears
  • Ear drainage visible by parent/guardian
  • Ear drainage less than 21 days
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Patients not otorrhea-free for 7 or less following tympanostomy tube surgery
  • Ear tube with antimicrobial activity; ear tube longer than 2.5mm
  • Non-tube otorrhea
  • No otic surgery other than tube placement in the last year
  • No menarchial females; no diabetic patients
  • No patients with any disease or condition that would negatively affect the conduct of the study
  • No patients taking any other systemic antimicrobial therapy during the study
  • Patient must meet certain medication washouts to be eligible
  • Analgesic use (other than acetaminophen) is not allowed
  • Patients may not be predisposed to neurosensory hearing loss
  • Other protocol-defined exclusion criteria may apply
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Moxidex

    Moxidex otic solution

    Drug: Moxidex otic solution · Device: Tympanostomy tubes

  • Active comparator
    Moxifloxacin

    Moxifloxacin otic solution

    Drug: Moxifloxacin otic solution · Device: Tympanostomy tubes

  • Placebo comparator
    Vehicle

    Vehicle

    Other: Vehicle · Device: Tympanostomy tubes

Interventions

  • DrugMoxidex otic solution

    Drug pages: Moxifloxacin · Dexamethasone phosphate

    4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

  • DrugMoxifloxacin otic solution

    4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

  • OtherVehicle

    4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

  • DeviceTympanostomy tubes

    Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

06

What researchers measure

Primary outcomes

  1. Clinical Cure at End of Treatment

    Time frame: Day 8

Secondary outcomes

  1. Time to Cessation of Otorrhea

    Time frame: From First Dose

  2. Microbiological Success at End of Treatment

    Time frame: Day 8

07

Study locations

1 site
  • Contact Alcon Call Center for Trial Locations
    Fort Worth, Texas 76134, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2010
First posted
Feb 19, 2010
Start
Feb 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results delay requested
Nov 28, 2012
Last update
Dec 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01071902
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Feb 19, 2010
Start date
Feb 2010
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Dec 3, 2012

Study contacts

Contact Alcon Call Center
study director · 1-888-451-3937

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Moxifloxacin · Dexamethasone phosphate

Start the discussion